Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US

Frontiers in Public Health

Xintian Wang¹  Hongchao Li¹  Aixia Ma¹  Ye Shang¹  Yingcheng Wang¹  Lan Yang¹  Mingjun Rui¹ 

[1] School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China;Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, China;

关键词: small-cell lung cancer;    cost-effectiveness;    atezolizumab;    chemotherapy;    extensive stage;   

DOI  :  10.3389/fpubh.2021.650392

来源: Frontiers

【 授权许可】

CC BY